Breast Carcinoma by Gene Expression Profile

subtype

Identifier: CI-CAN-00004666
Entity page: /cancer/breast-carcinoma-by-gene-expression-profile ↗
Edges: 1,467

Neighbours: 19 drugs10 trials
Drawn: 29 of 29 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Breast Carcinoma by Gene Expression Profile approved for …APPROVED_FORderived11 of 11
← approved for	Datopotamab Deruxtecanadc FDA (US) · approved · 2025-01-17 · This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.…	—	approved	Triple-Negative Breast Carcinoma	1	Regulatory	openfda	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

ERBB2 Amplification Trastuzumab40 active / 119 trials
Curatedlevel Asensitivity· support 14civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: HER2-Positive Breast Carcinoma
ERBB2 Amplification NeratinibFDA US 2017-07-178 active / 12 trials
Curatedlevel Asensitivity· support 2civicObservedcohort frequency not yet available for ERBB2 in this cancerRegulatoryapproved for HER2-Positive Breast Carcinoma (2 approval records)context: HER2-Positive Breast Carcinoma
BRCA1 Loss-of-function Olaparib11 active / 21 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA1 in this cancerno approval record in this cancercontext: Triple-Negative Breast Carcinoma
BRCA2 Loss-of-function Olaparib11 active / 21 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA2 in this cancerno approval record in this cancercontext: Triple-Negative Breast Carcinoma
ERBB2 Amplification Lapatinib0 active / 10 trials
Curatedlevel Bsensitivity· support 5civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: HER2-Positive Breast Carcinoma
ERBB2 Amplification Afatinib0 active / 3 trials
Curatedlevel Bsensitivity· support 4civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: HER2-Positive Breast Carcinoma
ERBB2 Amplification Trastuzumab Emtansine13 active / 28 trials
Curatedlevel Bsensitivity· support 4civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: HER2-Positive Breast Carcinoma
ERBB2 Amplification Capecitabine32 active / 69 trials
Curatedlevel Bsensitivity· support 2civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: HER2-Positive Breast Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Breast Carcinoma by Gene Expression Profile investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 159show all (up to 200)
→ investigated in trials for	Pembrolizumabmonoclonal antibody 145 trials (77 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	145	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 125 trials (59 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	125	Observed	clinicaltrials	graph →
→ investigated in trials for	Trastuzumabmonoclonal antibody 119 trials (40 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	119	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 116 trials (58 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	116	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 90 trials (35 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	90	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 69 trials (32 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	69	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 64 trials (26 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	64	Observed	clinicaltrials	graph →
→ investigated in trials for	Pertuzumabmonoclonal antibody 52 trials (28 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 49 trials (25 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	49	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 46 trials (20 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	46	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 37 trials (16 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	37	Observed	clinicaltrials	graph →
→ investigated in trials for	Sacituzumab Govitecanadc 32 trials (23 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 30 trials (8 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Trastuzumab Emtansineadc 28 trials (13 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Epirubicinsmall molecule 24 trials (9 active) · roll-up of the cancer and its descendants	—	—	Breast Carcinoma by Gene Expression Profile	24	Observed	clinicaltrials	graph →

Breast Carcinoma by Gene Expression Profile studied in …STUDIED_INderived10 of 1,297show all (up to 200)
→ studied in	NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ALIAS · 1,297 trials mapped (598 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05880160NA · completed Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction · condition mapped ALIAS · 1,297 trials mapped (598 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06586957Phase 1 · recruiting A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ALIAS · 1,297 trials mapped (598 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07152782Phase 2 · recruiting T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis · condition mapped ALIAS · 1,297 trials mapped (598 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07698106Phase 1/Phase 2 · not yet recruiting Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC · condition mapped ALIAS · 1,297 trials mapped (598 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02498613Phase 2 · active not recruiting A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors · condition mapped CURATED_BROADER · 1,297 trials mapped (598 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02945579NA · recruiting Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy · condition mapped ONTOLOGY_EXACT · 1,297 trials mapped (598 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04981119recruiting Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing · condition mapped ALIAS · 1,297 trials mapped (598 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05528133Phase 2 · recruiting Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer · condition mapped ALIAS · 1,297 trials mapped (598 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06393374Phase 3 · recruiting Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) · condition mapped ALIAS · 1,297 trials mapped (598 active)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →